Avalos’ Upcoming Investor Conferences Engagement
Avalo Therapeutics, Inc. (Nasdaq: AVTX), a biotechnology company dedicated to addressing immune dysregulation, has exciting news for investors and stakeholders. They recently announced plans for participation in significant upcoming investor conferences designed to provide insights into their innovative approaches in the biotech field.
HCW Annual Inflammation & Immunology Virtual Conference
One of the key events Avalo will feature in is the HCW Annual Inflammation & Immunology Virtual Conference slated for the end of June. During this session, the company management will partake in a fireside chat on June 30, providing a unique platform for discussing advancements in immune-related therapies.
BTIG Virtual Biotechnology Conference 2025
In addition to the HCW conference, Avalo will also engage in the BTIG Virtual Biotechnology Conference taking place at the end of July. Through individual meetings, they intend to connect directly with investors, fostering valuable conversations about their strategies and future growth potential.
Webcast Access and Company Insights
For those interested in the presentations, live webcasts, and recorded replays will be accessible through the “News / Events” section on the Avalo Therapeutics website. This initiative underlines their commitment to transparency and providing updated information to stakeholders, ensuring that all interested parties have access to critical discussions and developments.
About Avalo Therapeutics
Avalo Therapeutics is deeply entrenched in the biotech landscape, with a specific focus on treating immune dysregulation. They are driven by a mission to create innovative treatments that can improve the quality of life for patients grappling with various autoimmune and inflammatory conditions. Their flagship product, AVTX-009, is an anti-IL-1? monoclonal antibody that represents a promising approach to treating inflammatory diseases.
What Makes AVTX-009 Unique?
AVTX-009 targets interleukin-1? (IL-1?), a pivotal molecule in the inflammatory response. By neutralizing IL-1?, this therapy has the potential to make a significant impact on conditions such as hidradenitis suppurativa, as well as several other inflammatory disorders spanning dermatological, gastrointestinal, and rheumatological fields. The comprehensive research backing this therapeutic avenue highlights its relevance and the potential benefits it could deliver to patients.
Contact Information for Media and Inquiries
For those looking to reach out for further information, Avalo Therapeutics welcomes inquiries directed to Christopher Sullivan, CFO. He can be contacted via email at ir@avalotx.com or by phone at 410-803-6793. Avalo also collaborates with Meru Advisors for additional insights into their business initiatives. You can connect with Lauren Glaser via email at lglaser@meruadvisors.com.
Frequently Asked Questions
What is the focus of Avalo Therapeutics?
Avalo Therapeutics specializes in developing therapies for immune dysregulation conditions.
When will Avalo be participating in the HCW Conference?
Avalo will participate in the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025.
What is AVTX-009?
AVTX-009 is a monoclonal antibody targeting interleukin-1?, aimed at treating inflammatory diseases.
How can I access the investor presentations?
Live webcasts and recorded presentations will be available on the Avalo Therapeutics website.
Who can I contact for media inquiries?
For media inquiries, you can contact Christopher Sullivan at Avalo Therapeutics or reach out to Lauren Glaser from Meru Advisors.